Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia: Comparison with flavopiridol.

被引：3
|
作者：
Chen, Rong [1 ]
Wierda, William G. [1 ]
Benaissa, Sherri [1 ]
Hoch, Ute [2 ]
Hawtin, Rachael E. [2 ]
Fox, Judith A. [2 ]
Keating, Michael J. [1 ]
Gandhi, Varsha [1 ]
Plunkett, William [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Sunesis Pharmaceut, San Francisco, CA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3112.3112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3112
引用
收藏
页码：915A / 915A
页数：1
相关论文
共 50 条
  • [1] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
    Chen, Rong
    Wierda, William G.
    Chubb, Sherri
    Hawtin, Rachael E.
    Fox, Judith A.
    Keating, Michael J.
    Gandhi, Varsha
    Plunkett, William
    BLOOD, 2009, 113 (19) : 4637 - 4645
  • [2] Chemoprevention of Mouse Intestinal Tumorigenesis by the Cyclin-Dependent Kinase Inhibitor SNS-032
    Boquoi, Amelie
    Chen, Tina
    Enders, Greg H.
    CANCER PREVENTION RESEARCH, 2009, 2 (09) : 800 - 806
  • [3] The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine
    Walsby, E.
    Lazenby, M.
    Pepper, C.
    Burnett, A. K.
    LEUKEMIA, 2011, 25 (03) : 411 - 419
  • [4] The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine
    E Walsby
    M Lazenby
    C Pepper
    A K Burnett
    Leukemia, 2011, 25 : 411 - 419
  • [5] SNS-032. Cyclin-dependent kinase inhibitor, Oncolytic.
    Vasiliou, S.
    DRUGS OF THE FUTURE, 2008, 33 (11) : 932 - 937
  • [6] A PHASE I TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9 INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA
    Goldberg, Z.
    Wierda, W.
    Chen, R.
    Plunkett, W.
    Coutre, S.
    Badros, A.
    Popplewell, L.
    Fox, J. A.
    Hoch, U.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 316 - 316
  • [7] Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
    Blum, K. A.
    Ruppert, A. S.
    Woyach, J. A.
    Jones, J. A.
    Andritsos, L.
    Flynn, J. M.
    Rovin, B.
    Villalona-Calero, M.
    Ji, J.
    Phelps, M.
    Johnson, A. J.
    Grever, M. R.
    Byrd, J. C.
    LEUKEMIA, 2011, 25 (09) : 1444 - 1451
  • [8] Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)
    Lin, T. S.
    Andritsos, L. A.
    Jones, J. A.
    Fischer, B.
    Heerema, N. A.
    Blum, K. A.
    Flynn, J. M.
    Moran, M. E.
    Phelps, M. A.
    Grever, M. R.
    Byrd, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
    K A Blum
    A S Ruppert
    J A Woyach
    J A Jones
    L Andritsos
    J M Flynn
    B Rovin
    M Villalona-Calero
    J Ji
    M Phelps
    A J Johnson
    M R Grever
    J C Byrd
    Leukemia, 2011, 25 : 1444 - 1451
  • [10] Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS-032, on cervical cancer
    Kang, Mi Ae
    Kim, Wonwoo
    Jo, Hye-Ram
    Shin, Young-Joo
    Kim, Moon-Hong
    Jeong, Jae-Hoon
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (02) : 703 - 712
12345